EClinicalMedicine

Effectiveness and safety of HRS-7535, an oral diabetes drug, in people with diabetic kidney disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

The efficacy of HRS-7535, a novel oral small-molecule GLP-1 receptor agonist, in diabetic kidney disease is under evaluation.

  • The role of GLP-1 receptor agonists in diabetic kidney disease is not well established.
  • There is a specific focus on the effectiveness of HRS-7535 as an additional treatment option.
  • The study aims to clarify the potential benefits of this medication when used alongside current high-intensity therapies.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

LP, YX, XL, LL, and ZY are employees of Jiangsu Hengrui Pharmaceuticals. JC declares being the immediate past chair (unpaid) for the Chinese Medical Association (Nephrology Branch). LP, YX, XL, LL, and ZY declare a patent pending relating to HRS-7535. ZY declares owning stock in Jiangsu Hengrui Pharmaceuticals. RL, XD, HL, HW, YZ, QL, XJ, CP, and SY have nothing to disclose.
PubMed

Related papers

Jun '26
Elecoglipron, an oral drug activating GLP-1 receptors, tested in adults with type 2 diabetes in a multi-center phase 2b placebo-controlled trial
top 1% journal
cited by 1 paper
journal article
Jun '19
Effectiveness and safety of oral semaglutide in type 2 diabetes patients with moderate kidney problems
top 1% journal
cited by 274 papers
randomized controlled trial
Nov '25
Orforglipron, an oral GLP-1 drug, for treating obesity in people with type 2 diabetes: a phase 3 placebo-controlled trial
top 1% journal
cited by 32 papers
randomized controlled trial
Jun '19
Comparing oral semaglutide, injected liraglutide, and placebo in type 2 diabetes treatment
top 1% journal
cited by 472 papers
randomized controlled trial
Jun '23
Effectiveness and safety of different oral doses of orforglipron in people with type 2 diabetes
top 1% journal
cited by 138 papers
randomized controlled trial
Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 714 papers
randomized controlled trial

Featured in

GLP-1 TherapiesGLP-1 TherapiesIssue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
yesterday7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
1 week ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
2 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
3 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
4 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
5 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
6 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
7 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
8 weeks ago7 studies
issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief